Stock Scorecard



Stock Summary for Zymeworks BC Inc (ZYME) - $23.29 as of 3/2/2026 6:41:23 PM EST

Total Score

10 out of 30

Safety Score

39 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ZYME

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ZYME

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ZYME

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ZYME

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ZYME (39 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 6
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ZYME

Zymeworks (NASDAQ: ZYME) seals $250M Ziihera royalty financing 3/2/2026 11:29:00 AM
Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? 12/11/2025 11:09:00 PM
Could Zymeworks' blockbuster drug success revive Vancouver biotech scene? 12/10/2025 8:08:00 PM
Jazz, Zymeworks Bispecific Achieves ‘Practice-Changing’ Results in Stomach Cancer Study 11/18/2025 12:57:00 PM
Zymeworks stock hits four-year high on promising results from digestive cancer trial 11/17/2025 9:09:00 PM
Zymeworks (ZYME) Soars on Positive Phase 3 Ziihera Data in Gastric Cancer – What Today’s Breakthrough Means for the Stock and Patients 11/17/2025 8:08:00 PM
Opinion: Four trends to watch in B.C.'s tech sector 10/24/2025 2:02:00 AM
Zymeworks: Its Post-Approval Future (NASDAQ:ZYME) 10/24/2025 2:02:00 AM
FDA approves cancer drug developed by B.C.'s Zymeworks 10/24/2025 2:02:00 AM
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody 10/24/2025 2:02:00 AM

Financial Details for ZYME

Company Overview

Ticker ZYME
Company Name Zymeworks BC Inc
Country USA
Description Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops and markets biotherapeutic products for the treatment of cancer. The company is headquartered in Vancouver, Canada.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 9/30/2025
Next Earnings Date 3/2/2026

Stock Price History

Last Day Price 23.29
Price 4 Years Ago 7.86
Last Day Price Updated 3/2/2026 6:41:23 PM EST
Last Day Volume 547,381
Average Daily Volume 593,259
52-Week High 28.49
52-Week Low 9.03
Last Price to 52 Week Low 157.92%

Valuation Measures

Trailing PE N/A
Industry PE 26.08
Sector PE 46.86
5-Year Average PE -9.37
Free Cash Flow Ratio 26.77
Industry Free Cash Flow Ratio 12.68
Sector Free Cash Flow Ratio 25.71
Current Ratio Most Recent Quarter 6.94
Total Cash Per Share 0.87
Book Value Per Share Most Recent Quarter 4.26
Price to Book Ratio 5.68
Industry Price to Book Ratio 50.08
Sector Price to Book Ratio 52.77
Price to Sales Ratio Twelve Trailing Months 13.66
Industry Price to Sales Ratio Twelve Trailing Months 38.92
Sector Price to Sales Ratio Twelve Trailing Months 22.39
Analyst Buy Ratings 12
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 74,837,000
Market Capitalization 1,742,953,730
Institutional Ownership 96.90%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -3.39%
Reported EPS 12 Trailing Months -0.85
Reported EPS Past Year -0.53
Reported EPS Prior Year -1.61
Net Income Twelve Trailing Months -63,427,000
Net Income Past Year -122,695,000
Net Income Prior Year -118,674,000
Quarterly Revenue Growth YOY 72.60%
5-Year Revenue Growth 20.90%
Operating Margin Twelve Trailing Months -80.10%

Balance Sheet

Total Cash Most Recent Quarter 64,834,000
Total Cash Past Year 66,103,000
Total Cash Prior Year 157,557,000
Net Cash Position Most Recent Quarter 64,834,000
Net Cash Position Past Year 66,103,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 338,768,000
Total Stockholder Equity Prior Year 464,806,000
Total Stockholder Equity Most Recent Quarter 320,064,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -66,200,000
Free Cash Flow Per Share Twelve Trailing Months -0.88
Free Cash Flow Past Year -113,110,000
Free Cash Flow Prior Year -122,380,000

Options

Put/Call Ratio 0.87
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.07
MACD Signal -0.27
20-Day Bollinger Lower Band 16.44
20-Day Bollinger Middle Band 22.90
20-Day Bollinger Upper Band 29.37
Beta 1.24
RSI 56.05
50-Day SMA 17.04
150-Day SMA 12.56
200-Day SMA 11.22

System

Modified 2/26/2026 12:02:53 PM EST